Drug Database
ET

etoposide

✓ Approved

Pierre Fabre S.A. · TOP2A · 小分子

什么是 etoposide?

etoposide 是一种小分子,由Pierre Fabre S.A.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

公司Pierre Fabre S.A.
药物类别小分子
分子靶点TOP2A
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

etoposide 作用于 1 个分子靶点:

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

etoposide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasm malignant✓ Approved

相关研究文献

PubMedCancer reports (Hoboken, N.J.)2026-11-17

Clinically Presumed Brain Metastasis as the Initial Presentation of Prostate Cancer Harboring a BRCA2 Alteration With Subsequent Transformation to Treatment-Related Neuroendocrine Prostate Cancer: A Case Report.

Wang Yanwu Y, Wu Yingjie Y, Zhu Shaokang S, Wu Zhengrong Z et al.

Treatment-related neuroendocrine prostate cancer (t-NEPC) is an aggressive, therapy-resistant phenotype for which no standard treatment has been established. Intracranial metastasis from prostate cancer is uncommon, particularly as the initial presentation. In March 2020, a 62-year-old man presented to Nanfang Hospital, Southern Medical University, Guangzhou, China, with dizziness and blurred vision. Imaging showed disseminated prostate cancer and an intracranial lesion that was clinically presumed to represent metastasis but was not biopsied. Prostate biopsy demonstrated acinar adenocarcinoma (Gleason score 5 + 4 = 9; Grade Group 5). After androgen deprivation therapy, docetaxel, and subsequent abiraterone, a February 2022 transurethral resection specimen showed large-cell neuroendocrine carcinoma, establishing t-NEPC in the prostate. Immediately before TURP, total PSA was 0.369 ng/mL and NSE was 30.3 ng/mL. Tumor-only next-generation sequencing of the resection specimen detected BRCA2 p.I605fs and TP53 p.A83fs alterations with RB1 and PTEN copy-number losses; germline status was not assessed. Etoposide/cisplatin was initiated in March 2022, and continuous olaparib began on April 14, 2022 during cycle 2. Clinical improvement and approximately 11 months of disease stability were observed, but the contribution of either treatment cannot be isolated. The disease subsequently progressed, and the patient died 39 months after the initial diagnosis. This case underscores the distinction between a clinically presumed intracranial metastasis and histologically confirmed t-NEPC. It also highlights the diagnostic value of re-biopsy at progression and the need for cautious interpretation of biomarker changes and overlapping treatments. Prospective clinicopathological and molecular data are needed to refine the diagnosis and management of t-NEPC.

PMID 43039876
阅读全文 →
PubMedGan to kagaku ryoho. Cancer & chemotherapy2026-11-16

[A Case of Chronic Encapsulated Expanding Hematoma Following Gamma Knife Radiosurgery for a Brain Metastasis from Large-Cell Neuroendocrine Carcinoma of the Lung].

Ohno Kyoichi K, Sakaguchi Koji K, Yomo Shoji S, Yamazaki Yoshitaka Y et al.

A 69-year-old man with large-cell neuroendocrine carcinoma of the left lung accompanied by brain and rectal metastases underwent Gamma knife radiosurgery followed by chemotherapy with atezolizumab, etoposide, and carboplatin, achieving a complete response. During maintenance therapy, enlargement of the treated brain lesion caused right lower extremity paresis; therefore, repeat Gamma knife radiosurgery was performed. Three years later, the recurrent paresis recurred. Contrast-enhanced magnetic resonance imaging revealed a well-circumscribed lesion with a thick capsule in the left parietal lobe. Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging showed no abnormal uptake. Recurrent brain metastasis and chronic encapsulated expanding hematoma were considered in the differential diagnosis. A craniotomy and lesion resection were performed. Histopathological examination demonstrated an organized hematoma without viable malignant cells, leading to the diagnosis of chronic encapsulated expanding hematoma. The neurological deficit improved postoperatively. Chronic encapsulated expanding hematoma should therefore be considered in the differential diagnosis of recurrent brain metastasis after stereotactic radiosurgery.

PMID 43039378
阅读全文 →
PubMedRespirology case reports2026-11-15

Small Cell Lung Cancer Developing After Regression of Clinically Suspected Methotrexate-Associated Lymphoproliferative Disorder: A Diagnostic Pitfall in Rheumatoid Arthritis.

Nagayoshi Takuma T, Kai Yoshiro Y, Takano Masato M, Suzuki Kentaro K et al.

Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a complication of methotrexate therapy in patients with rheumatoid arthritis (RA). Distinguishing suspected MTX-LPD from a new malignancy can be challenging when thoracic lesions appear after regression of earlier lesions. In a 69-year-old man with RA, MTX-LPD was clinically suspected but not histopathologically confirmed during methotrexate therapy. Multiple pulmonary nodules, bilateral adrenal masses and an anterior chest wall lesion regressed after methotrexate withdrawal and corticosteroid therapy. Prednisolone was increased to prevent worsening of RA after methotrexate withdrawal. Approximately 15 months later, he presented with dyspnoea and chest computed tomography revealed multiple right pleural nodules, pleural thickening and pleural effusion. The pleural lesions differed in distribution from the initial abnormalities. Pleural fluid cytology suggested small cell carcinoma and computed tomography-guided biopsy established a diagnosis of small cell lung cancer. Chemotherapy with carboplatin and etoposide resulted in tumour regression and reduced pleural effusion. This case emphasizes that regression following methotrexate withdrawal does not establish MTX-LPD and that new or atypical thoracic lesions warrant renewed diagnostic assessment and tissue confirmation.

PMID 43032111
阅读全文 →
PubMedOncology letters2026-11-15

Ectopic olfactory neuroblastoma - complete response to chemotherapy following a late recurrence: A case report.

Pérez Reyes Juan Ernesto JE, Santiesteban González Eliécer Alcides EA, González Cabrera Miriela De La Caridad MC, Martínez Sedeño Magda Caridad MC et al.

Olfactory neuroblastoma, also known as esthesioneuroblastoma, is a rare type of cancer that originates in the nerve tissue of the olfactory epithelium, located in the upper part of the nasal cavity. The present study reports the case of a female patient who was 35 years old at the time of diagnosis in 2013, with an ectopic olfactory neuroblastoma (Hyams grade III, Kadish stage B) in the right sphenoid sinus, associated with the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (SIADH). Following transnasal endoscopic surgical resection and adjuvant intensity-modulated radiotherapy (60 Gy) in 2014, the SIADH resolved and the patient achieved complete remission. After a 10-year latency period, in April 2024 the patient developed a late, destructive local recurrence (5.3×4.7 cm) with extension to the maxillary sinus and right orbit. Given the technical limitations for salvage surgery and the refusal of re-irradiation, a multidisciplinary committee approved the administration of 6 cycles of systemic chemotherapy with cisplatin (75 mg/m2) and etoposide (100 mg/m2) every 21 days. Treatment began in June 2024 and concluded in September 2024. Treatment was well tolerated, with only grade 1 nausea and transient grade 2 myelosuppression. Close follow-up with contrast-enhanced head and neck CT in December 2025 confirmed the complete clinical and radiological response, demonstrating the total absence of the tumor lesion. As of February 2026, the patient remains asymptomatic and disease-free. The present case highlights the rarity of ectopic sphenoid location, the usefulness of SIADH as an indirect biomarker and the high chemosensitivity of high-grade variants in late recurrences, justifying prolonged and indefinite follow-up.

PMID 43031906
阅读全文 →
PubMedJournal of medical case reports2026-11-14

Etoposide-induced angina in a patient with small cell lung carcinoma: a case report.

Otsuka Shinya S, Chiba Yasuyuki Y, Otsuka Kenta K, Shimazu Kyo K et al.

The combination of cisplatin and etoposide is a standard therapy for small cell lung cancer; however, ischemic heart disease is a known complication. We report a rare case of effort angina pectoris that worsened during initial treatment of small cell lung cancer with etoposide. A 73-year-old Asian male was admitted to our hospital with effort angina. Coronary angiography revealed severe stenosis with significant calcification of the proximal right coronary artery. Computed tomography revealed a 21-mm-sized nodule in the right upper lobe and hilar lymphadenopathy suggestive of lung cancer. The patient underwent thoracoscopic wedge resection before coronary revascularization, and intraoperative findings indicated a small cell carcinoma with hilar lymph node metastases. Early postoperative definitive treatment consisting of chemotherapy with cisplatin plus etoposide and accelerated hyperfractionated radiation was planned. During the first chemotherapy session, on postoperative day 7, the patient complained of chest pain, and an electrocardiogram showed slight ST depression in leads V5 and V6 while receiving etoposide; nitroglycerin improved his symptoms. Although treatment was resumed with the administration of nicorandil the next day, the same symptoms were observed during the infusion of etoposide. Accordingly, chemoradiation therapy was suspended and revascularization of the right coronary artery was performed. Etoposide and cisplatin were readministered 3 days after revascularization, without any chest symptoms. Chemotherapy for malignant tumors carries the risk of progression to coronary artery disease. To prevent serious ischemic events, sufficient discussions between oncologists and cardiologists and careful observation of chest symptoms are needed.

PMID 43026561
阅读全文 →
PubMedCancers2026-11-14

Pulmonary Large-Cell Neuroendocrine Carcinoma: Molecular Heterogeneity, Current Treatment and the Emerging Precision-Oncology Paradigm.

Lee Tai-Huang TH, Ma Juei-Yang JY, Hung Huei-Yang HY, Kuo Chia-Yu CY et al.

Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive malignancy with substantial biological heterogeneity. Genomic studies identify SCLC-like and NSCLC-like spectra, but genomic categories overlap incompletely with transcriptional states. Morphology remains essential: neither neuroendocrine marker positivity nor RB1 status alone distinguishes LCNEC from small-cell lung cancer (SCLC). This narrative review integrates diagnostic limitations, stage-based management, and the clinical implications of profiling. Surgery with systematic nodal assessment is central for resectable disease; postoperative platinum chemotherapy has greater support than perioperative immunotherapy. In advanced disease, platinum-etoposide is a commonly used reference regimen. Retrospective associations involving platinum-gemcitabine or platinum-taxanes in RB1-wild-type tumors remain hypothesis-generating and should not be extended to pemetrexed. LANCE, a durvalumab phase II trial, and preliminary NEJ044 findings provide prospective chemo-immunotherapy observations, although randomized LCNEC-specific evidence remains absent. No standard second-line regimen is established. Rare actionable drivers may support matched treatment, whereas DLL3-directed approaches and FGL1/SPINK1-associated strategies require clinical validation. We propose an evidence-qualified framework separating stage-based care, individualized molecular considerations, and clinical-trial strategies.

PMID 43026905
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多etoposide